New hope for stage 4 lung cancer? trial combines experimental drug with standard therapy
NCT ID NCT07365319
First seen Feb 01, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study tests whether adding an experimental drug (EIK1001) to standard treatment (pembrolizumab plus chemotherapy) helps people with stage 4 non-small cell lung cancer live longer or stop their cancer from growing. About 750 adults whose cancer has spread will receive either the new combination or a placebo plus standard therapy. The goal is to see if the new drug improves outcomes without causing unacceptable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 4 NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.